Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may cause low oxygen saturation (SpO2) and respiratory failure in coronavirus disease (COVID-19) patients. Hence the increase of SpO2 levels could be crucial for the quality of life and recovery of these patients. Here we introduce an electromagnetic device termed low-field thoracic magnetic stimulation (LF-ThMS) system. This device was designed to non-invasively deliver a pulsed magnetic field from 100 to 118 Hz and 10.5 to 13.1 mT (i.e., 105 to 131 Gauss) to the dorsal thorax. We show that these frequencies and magnetic flux densities are safe for the patients. We also present a proof-of-concept that a single session of LF-ThMS applied for 30 minutes to the dorsal thorax of 17 COVID-19 patients significantly increases their SpO2 levels. We designed a single-blind, sham-controlled, crossover study on 5 COVID-19 patients who underwent two sessions of the study (real and sham LF-ThMS) and 12 COVID-19 patients who underwent only the real LF-ThMS. We found a statistically significant correlation between magnetic flux density, frequency, or temperature associated with the real LF-ThMS and SpO2 levels in all COVID-19 patients. However, the five patients of the sham-controlled study did not exhibit a significant change in their SpO2 levels during sham stimulation. All the patients did not present adverse events after the LF-ThMS intervention.
Trial registration ClinicalTrials.gov
Identifier NCT04895267
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04895267
Funding Statement
Centro de Investigacion de Micro y Nanotecnologia (SMDN), National Council of Science and Technology, Mexico, CONACyT Fronteras de la Ciencia 536 (EM), Catedra Marcos Moshinsky (EM), and VIEP-PIFI-FOMES-PROMEP-BUAP-Puebla (EM), Comite de Internacionalizacion and VIEP BUAP (EM), Mexico.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical trial was registered by the local ethics committee from the Faculty of Medicine from Benemerita Universidad Autonoma de Puebla, Mexico (protocol: Oficio No. SIEP/C.I./065A/2020, book number: 2, sheet number: 133, registration number: 818, date: July 3, 2020).The study was registered in ClinicalTrials.gov (Identifier: NCT04895267). We declare that all relevant ethical guidelines have been followed and ethics committee approval has been obtained. All necessary patient/participant consent has been obtained. SPIRIT-Checklist was included as a supplementary file.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that all data underlying the findings are fully available without restriction upon request. All relevant data are within the paper.
